Navigation Links
NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference

BETHESDA, Md., March 19, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Linda F. Powers , the Company's Chairman and Chief Executive Officer, will be presenting at the 25th Annual ROTH Conference at 8:30 a.m. PDT on Wednesday, March 20, 2013, at the Ritz-Carlton, Laguna Niguel, Dana Point, California.


Ms. Powers' presentation will discuss the Company's lead Phase III trial with DCVax-L for brain cancer, including guidance on enrollment, progress in Europe, and anticipated timelines for major milestones.  Ms. Powers will also discuss the Company's pending Phase I/II trial with DCVax-Direct for all solid tumor cancers that are inoperable, which is preparing to launch in Q2.  Ms. Powers will comment on the Company's key strengths and differentiation in the immune therapy space, and will announce certain new developments.

The presentation will take place in Track 8 of the conference, in The Promenade – White Room, and will be available by web cast at  The webcast will remain available for 90 days following the presentation.  It will also be available on the NW Bio Website starting on Thursday, March 21, 2013, at

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe.  The Company has a broad platform technology for DCVax® dendritic cell-based vaccines.  The Company's lead program is a 312-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal brain cancer.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I/II trials in multiple other cancers.  The Company has also conducted a Phase I/II trial with DCVax® for metastatic ovarian cancer together with the University of Pennsylvania. 


Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax® and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.                                                                                                                                                                                                           

SOURCE Northwest Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. At RSNA, DR Systems Will Exhibit RIS, Reporting, Peer Review Systems
2. Nucleic Acids Research Journal Publishes Sapphire Energy Peer-Reviewed Research Paper on a Chloroplast Genome From Green Algae
3. Unigenes 2011 Year in Review - Key Elements in Place to Address Debt in 2012
4. FDAs Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone New Drug Application on February 9, 2012
5. Nonprofit Consortium Publishes Review of Skullcap Adulteration
6. Peer-reviewed Article Reports ProImmune's Immune Formulation 200® Activates the Immune-Support Gene Nrf2.
7. Vitamin D Deficiency Disorders Global Clinical Trials Review, H2, 2012
8. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Second Quarter 2012 Financials
9. Inflammatory Bowel Disease Global Clinical Trials Review, H2, 2012
10. Alzheimers Therapeutics Reviewed by NeuroPerspective
11. Peer Reviewed Clinical Study Shows New Blood Test More Accurately Predicts Risk Of A Heart Attack
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... InSphero AG , ... 3D cell culture models, has launched a 14 Day Hepatotoxicity Testing Service ... InSightâ„¢ Human Liver Microtissues. The service streamlines toxicity testing of compounds in ...
(Date:10/13/2015)... 2015 ARRY ), Avanex Life ... JUNO ), and Progenix Pharmaceuticals, Inc. (NASDAQ: PGNX ... Corp. (OTCQX: AVXLD), Juno Therapeutics, Inc. (NASDAQ: JUNO ... --> Cooperative research and development efforts with ... lead to advancements in the treatment of severe wounds. ...
(Date:10/13/2015)... , Oct. 13, 2015  According to ... services will reach $102 billion by the end ... of the health industry, as it is estimated ... result of laboratory tests. In addition to diagnosing ... to evaluate disease progression, monitor drug treatment and ...
(Date:10/13/2015)... ... October 13, 2015 , ... Proove Biosciences, a ... their partnership with the Keck Medicine of the University of Southern California ... T.R.O.J.A.N. Study (Therapeutic Evaluation to Research Clinical Objectives Linking Genotypic and Phenotypic Association ...
Breaking Biology Technology:
(Date:10/6/2015)... Calif. , Oct. 6, 2015  Maverix ... today announced enhancements to its software portfolio with ... analysis kit for differential expression in eukaryotes. The ... which is a cloud-based genomic analysis solution that ... scientific discovery from next-generation sequencing efforts. ...
(Date:10/2/2015)... -- ) has announced ... Using Biometrics" report to their offering. ... of the "Enforcing the Law Using Biometrics" ... Research and Markets ( ) has announced ... Using Biometrics" report to their offering. ...
(Date:9/30/2015)... -- With nearly 300,000 Americans living with spinal cord injuries ... reach 12,500 annually, the role of Independent Living Centers ... Living (SCRS-IL) is increasingly important. SCRS-IL is one ... opening doors to independence for individuals with SCIs by ... technology services and education. "In serving people ...
Breaking Biology News(10 mins):